Cytek Biosciences, Inc. ( CTKB ) NASDAQ Global Select

Cena: 4.14 ( 3.12% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Medical - Devices
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Cytek Biosciences, Inc., firma analizy analizy komórkowej, zapewnia narzędzia analizy komórkowej, które ułatwiają postępy naukowe w badaniach biomedycznych i zastosowaniach klinicznych. Oferuje systemy Aurora i Northern Lights, które są cytometami przepływowymi spektrum, które dostarczają analizę komórek, wykorzystując sygnatury fluorescencyjne z wielu laserów w celu odróżnienia fluorescencyjnych znaczników na pojedynczych komórkach; oraz system sorterów komórek Aurora, który wykorzystuje technologię profilowania pełnego widma w celu dalszego poszerzenia potencjalnych zastosowań w analizie komórek. Firma zapewnia również odczynniki i zestawy, w tym odczynniki Cfluor, które są przeciwciałami sprzężonymi z fluorochromem stosowanymi do identyfikacji komórek zainteresowanych do analizy jej instrumentów, a także 25-kolorowych testów immunoprofilkowych, które zapewniają roztwory pod klucz do identyfikacji głównych ludzkich subpopulacji immunologicznych dla komórek TBNK, monocytów, komórek zdewrytowych i bazowych. Ponadto oferuje zautomatyzowany system mikro-próbkowania i zautomatyzowany system ładowań próbnych, które są automatycznymi ładowarami płytowymi do płynnej integracji z systemami zorzy polarnej i Northern Lights; Oprogramowanie SpectROFLO, które zapewnia intuicyjny przepływ pracy od kontroli jakości do analizy danych dla systemów Aurora i Northern Lights; i narzędzia do obsługi klienta. Firma obsługuje firmy farmaceutyczne i biofarma, akademickie centra badań i organizacje badawcze kliniczne. Dystrybuuje swoje produkty za pośrednictwem organizacji sprzedaży bezpośredniej i wsparcia w Ameryce Północnej, Europie, Chinach i regionie Azji i Pacyfiku; oraz za pośrednictwem dystrybutorów lub agentów sprzedaży w krajach europejskich, Ameryki Łacińskiej, Bliskiego Wschodu i Azji i Pacyfiku. Firma była wcześniej znana jako Cytoville, Inc. i zmieniła nazwę na Cytek Biosciences, Inc. w sierpniu 2015 r. Cytek Biosciences, Inc. został założony w 1992 roku i ma siedzibę w Fremont w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 645
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 86.3791
Ilość akcji: Brak danych
Debiut giełdowy: 2021-07-23
WWW: https://cytekbio.com
CEO: Dr. Wenbin Jiang Ph.D.
Adres: 47215 Lakeview Boulevard
Siedziba: 94538 Fremont
ISIN: US23285D1090
Wskaźniki finansowe
Kapitalizacja (USD) 526 071 240
Aktywa: 491 226 000
Cena: 4.14
Wskaźnik Altman Z-Score: 5.7
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -82.7
Ilość akcji w obrocie: 86%
Średni wolumen: 1 256 064
Ilość akcji 127 224 000
Wskaźniki finansowe
Przychody TTM 201 210 000
Zobowiązania: 105 763 000
Przedział 52 tyg.: 2.37 - 7.63
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -0.1
P/E branży: 29.9
Beta: 1.321
Raport okresowy: 2025-11-04
WWW: https://cytekbio.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Wenbin Jiang Ph.D. President, Chief Executive Officer & Chairman of the Board 939 242 1964
Ms. Valerie T. Barnett J.D. Chief Legal Officer & Corporate Secretary 612 394 1975
Dr. Allen B. Poirson Ph.D. Senior Vice President of Business & Corporate Development 576 276 1960
Dr. Ming Yan Ph.D. Chief Technology Officer & Director 570 122 1963
Mr. Patrik Sebastian Jeanmonod Head of Corporate Development Analytics 536 088 1967
Dr. Philippe Busque Ph.D. Senior Vice President of Global Sales & Services 0 1971
Mr. William D. McCombe Chief Financial Officer 0 1958
Mr. Chris Williams Chief Operating Officer 0 1969
Lista ETF z ekspozycją na akcje Cytek Biosciences, Inc.
Symbol ETF Ilość akcji Wartość
IJR 6 038 586 21 738 907
IWM 2 782 826 10 018 174
IWN 999 561 3 598 418
IJS 962 785 3 466 024
SPSM 923 465 3 286 453
IBB 693 018 2 494 865
VTWO 598 511 2 034 937
SLYV 550 615 1 980 007
SCHA 483 778 1 699 574
VHT 343 710 1 168 614
VIOO 339 755 1 155 167
DFAS 333 845 1 201 842
DFAT 299 411 1 077 879
AVSC 235 304 835 329
VIOV 208 409 708 590
R2US.L 195 411 693 709
ZPRR.DE 195 411 607 481
R2SC.L 195 411 525 685
DRDR.L 161 305 439 518
HEAL.L 161 305 580 698
2B78.DE 161 305 507 994
FESM 155 148 581 805
IUS3.DE 141 369 445 210
ISP6.L 141 369 385 197
IDP6.L 141 369 508 928
DFAC 110 476 397 713
ITOT 108 121 389 236
GSSC 106 125 379 927
WLDS.L 105 298 286 912
IUSN.DE 105 298 331 612
WSML.L 105 298 379 072
PSCH 98 363 349 188
PRFZ 92 699 329 081
DFSV 79 031 284 511
VTWV 77 595 263 823
XRSG.L 72 183 19 691 930
XRS2.DE 72 183 227 559
XRSU.L 72 183 259 860
PSC 65 916 237 297
RWJ 61 695 219 017
RSSL 59 476 214 113
FHLC 48 598 182 242
EES 37 461 134 859
IJR.AX 36 243 198 971
IWV 27 259 98 132
DFAU 22 561 81 219
XSU.TO 20 313 99 533
SXRG.DE 16 743 52 728
CSUSS.MI 16 743 52 728
CUSS.L 16 743 60 275
CUS1.L 16 743 45 621
SPTM 15 491 55 127
QVMS 13 650 48 457
ZPRV.DE 12 910 34 959
USSC.L 12 910 39 922
UWM 11 899 42 836
WOSC.L 11 500 30 936
WDSC.L 11 500 40 825
ZPRS.DE 11 500 35 750
AVUS 11 447 40 636
URTY 9 849 35 456
VTHR 9 813 33 364
XJR 8 047 28 566
XUU.TO 3 991 19 558
XSMC.TO 3 616 17 719
XSMH.TO 3 345 16 390
SAA 1 891 6 807
XGRO.TO 1 372 6 724
SPGM 1 349 4 800
VLU 1 191 4 251
XBAL.TO 632 3 095
XUH.TO 589 2 090
HDG 142 511
XCNS.TO 50 242
XTR.TO 24 84
USUE.DE 0 0
RTYS.L 0 40 168
USFM.L 0 0
PZW.TO 0 1 551
USML.L 0 52 702
SC0K.DE 0 35 195
Wiadomości dla Cytek Biosciences, Inc.
Tytuł Treść Źródło Aktualizacja Link
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-05-12 00:30:33 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. zacks.com 2025-05-08 23:10:40 Czytaj oryginał (ang.)
Cytek Biosciences Reports First Quarter 2025 Financial Results FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. globenewswire.com 2025-05-08 20:05:00 Czytaj oryginał (ang.)
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued? The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in 2024, its operating expenses represented 65.67% of its sales. In 2024, the company reported cash and cash equivalents and marketable securities of $277.86 million. Meanwhile, its total liabilities were $103.76 million in that year. seekingalpha.com 2025-05-05 12:14:19 Czytaj oryginał (ang.)
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025 Cytek Biosciences is showcasing its patented Full Spectrum Profiling™ technology at CYTO 2025 & American Association of Immunologists' (AAI) IMMUNOLOGY2025 globenewswire.com 2025-04-29 21:00:00 Czytaj oryginał (ang.)
Why Cytek Biosciences Should Beat Q1 Earnings Expectations There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future growth prospects. seekingalpha.com 2025-04-28 12:15:00 Czytaj oryginał (ang.)
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. globenewswire.com 2025-04-24 20:05:00 Czytaj oryginał (ang.)
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer, creating a next-generation instrument called the Cytek® Muse® Micro. globenewswire.com 2025-03-18 19:00:00 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today. seekingalpha.com 2025-02-28 11:49:10 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. zacks.com 2025-02-27 21:15:23 Czytaj oryginał (ang.)
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. globenewswire.com 2025-02-27 18:05:00 Czytaj oryginał (ang.)
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. globenewswire.com 2025-02-13 18:05:00 Czytaj oryginał (ang.)
Cytek Biosciences to Participate in Upcoming Investor Conferences FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. globenewswire.com 2025-02-05 18:05:00 Czytaj oryginał (ang.)
Upgrading Cytek Biosciences Stock On An Upcoming Catalyst I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions. seekingalpha.com 2025-01-09 11:30:00 Czytaj oryginał (ang.)
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. globenewswire.com 2025-01-02 10:00:00 Czytaj oryginał (ang.)
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025 FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. globenewswire.com 2024-12-30 10:00:00 Czytaj oryginał (ang.)
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY. globenewswire.com 2024-11-20 18:05:00 Czytaj oryginał (ang.)
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. globenewswire.com 2024-11-19 19:00:00 Czytaj oryginał (ang.)
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system. globenewswire.com 2024-11-07 19:00:00 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-11-05 22:26:10 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago. zacks.com 2024-11-05 20:15:17 Czytaj oryginał (ang.)
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe. globenewswire.com 2024-09-18 21:00:00 Czytaj oryginał (ang.)
Cytek Announces Resignation of Chief Operating Officer Chris Williams FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. globenewswire.com 2024-09-12 19:20:00 Czytaj oryginał (ang.)
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification. globenewswire.com 2024-08-21 21:00:00 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today. seekingalpha.com 2024-08-11 08:25:27 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago. zacks.com 2024-08-06 23:22:08 Czytaj oryginał (ang.)
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes. globenewswire.com 2024-07-30 21:00:00 Czytaj oryginał (ang.)
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last? Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-06-24 13:36:43 Czytaj oryginał (ang.)
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. globenewswire.com 2024-05-30 20:05:00 Czytaj oryginał (ang.)
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration (NMPA) approval for clinical diagnostic use on the Cytek® Northern Lights™-Clinical (NL-CLC™) cell analysis systems in hospitals, laboratories and clinics across China. globenewswire.com 2024-05-28 21:30:00 Czytaj oryginał (ang.)
Lab Instrument Industry Update - New Commercial Entrants Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. seekingalpha.com 2024-05-23 13:17:40 Czytaj oryginał (ang.)
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. globenewswire.com 2024-05-20 21:30:00 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Jake Siewert - Goldman Sachs David Westenberg - Piper Sandler Noah Krozel - Raymond James Mason Carrico - Stephens Jacqueline Kisa - TD Cowen Operator Thank you for standing by. My name is Liz, and I'll be your conference operator today. seekingalpha.com 2024-05-12 07:24:07 Czytaj oryginał (ang.)
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago. zacks.com 2024-05-09 00:31:21 Czytaj oryginał (ang.)